Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice
Open Access
- 30 December 2010
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (4), 553-562
- https://doi.org/10.1111/j.1365-2125.2010.03899.x
Abstract
The management of patients with congenital haemophilia who develop alloantibodies against factors of the propagation phase of blood coagulation, commonly known as inhibitors, is the most important challenge facing haemophilia caregivers at present, as this complication not only compromises the efficacy of replacement therapy but also consumes an enormous amount of economic resources. Development of inhibitors further complicates the clinical course of severe haemophilia, with a prevalence of up to 30% in patients with haemophilia A (factor VIII deficiency) and up to 5% in those with haemophilia B (factor IX deficiency) and haemophilia C (factor XI deficiency). While the short‐term goal of treatment of patients who develop alloantibodies is the control of bleeding, the eradication of the inhibitor is the main long‐term goal. The management of severe bleeding episodes and the eradication of the autoantibody are also the mainstays of treatment of patients with acquired haemophilia, a rare but life‐threatening haemorrhagic condition characterized by the development of inhibitory autoantibodies against coagulation factor VIII. The most recent options available for treating patients with congenital haemophilia complicated by inhibitors and acquired haemophilia because of autoantibodies against factor VIII are summarized in this review article.Keywords
This publication has 96 references indexed in Scilit:
- Safety of Recombinant Activated Factor VII in Randomized Clinical TrialsNew England Journal of Medicine, 2010
- International recommendations on the diagnosis and treatment of patients with acquired hemophilia AHaematologica, 2009
- Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysisHaemophilia, 2008
- Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisalHaemophilia, 2007
- Inhibitor Development in Hemophiliacs: The Roles of Genetic versus Environmental FactorsSeminars in Thrombosis and Hemostasis, 2006
- Acquired hemophilia A: A concise reviewAmerican Journal of Hematology, 2005
- Treatment of acquired hemophilia by the Bonn-Malmö Protocol: documentation of an in vivo immunomodulating conceptBlood, 2005
- Inhibitors against factor VIII in patients with cancerCancer, 2001
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIINew England Journal of Medicine, 1988
- Corticosteroid Therapy for Acquired F VIII:C InhibitorsBritish Journal of Haematology, 1981